/

IXHL

Incannex Healthcare Inc.Closed

2.86−0.05 −1.72%USD

NasdaqCM · as of Oct 14, 16:00 ET · 15m delayAfter hours 2.87 +0.52%

Open

2.91

Prev close

2.91

Day range

2.842.92

52-week range

2.4914.91

Volume

79.71K0.90×

Mkt cap

35.88M

P/E ttm

—

Fwd P/E

-1.68

EPS ttm

-1.62

Div yield

0.00%

Earnings

—

From 52w high

−80.82%

Price Chart

Yahoo Finance · delayed

IXHLOct 14, 2026O 2.91H 2.93L 2.84C 2.86−0.05 (−1.72%)Vol 79.50K

SMA 503.32
SMA 2004.73

1Y change −76.63% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IXHL Incannex Healthcare Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −10.06%
1 month: −13.07%
3 months: −11.46%
6 months: −21.21%
Year to date: −73.37%
1 year: −74.98%

Valuation & ownership

Market cap: 35.88M
Enterprise value: −31.74M
P/E (ttm): —
Forward P/E: -1.68
PEG ratio: —
Price / book: 0.53
Price / sales (ttm): —
EV / EBITDA: 1.75
EPS (ttm): -1.62
EPS (forward): -1.71
Beta (5y monthly): 2.82
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 12.54M
Float: 10.18M
Short % of float: 3.68%
Short ratio (days): 4.74
Held by insiders: 11.77%
Held by institutions: 3.64%
Avg volume (3m): 88.31K
50-day average: 3.32
200-day average: 4.73
52-week change: −74.98%
S&P 500 52-week: +15.71%

Technicals (daily)

RSI (14): 32.2
vs 50-day SMA: −13.86%
vs 200-day SMA: −39.57%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.69%
Realised vol (20d, ann.): 44.1%
From 52-week high: −80.82%
From 52-week low: +14.86%

ANR

Analyst Consensus

2 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

18.67

+552.92% implied

Low 18.02Median 18.67High 19.33

Recommendation trend

Now1 / 0 / 0
1m ago1 / 0 / 0

Buy / hold / sell counts

DES

About Incannex Healthcare Inc.

Yahoo Finance profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. The company is headquartered in Melbourne, Australia.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 12
Headquarters: Melbourne, VIC, Australia
Website: incannex.com
Officers: Mr. Joel Bradley Latham President, CEO & Executive Director
Mr. Joseph Swan CFO, Treasurer & Secretary
Dr. Luigi M. Barbato M.D. Chief Medical Officer
Mr. Lekhram Changoer M.Sc.

SEAS

Seasonality · IXHL

2022–2026 · monthly returns

Strongest month Jul +31.24%Weakest month Apr −31.66%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-13.4	-54.4	-29.2	46.3	-23.7	12.2	-21.8	13.9	-3.3	-11.7			−73.4%
2025	-21.2	-24.0	-46.7	-78.1	41.9	2.9	170.8	12.6	-29.6	-18.7	-4.5	-0.6	−83.1%
2024	-25.9	57.8	-33.9	-19.5	-2.1	3.9	-35.0	-7.9	13.1	14.1	-21.6	19.1	−54.3%
2023	15.4	-21.1	-13.5	-2.1	-12.0	-3.4	-1.4	-19.9	-21.6	-7.7	90.2	-41.9	−58.6%
2022				-26.9	9.0	-47.2	-9.5	20.9	2.9	-8.8	2.3	-30.9	−69.4%

INSD

Insider Activity · IXHL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Nov 13, 2025	Latham JoelChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	22.61M	—
Nov 13, 2025	Anastassov GeorgeDirector	Stock Award(Grant) at price 0.00 per share.	1.69M	—
Nov 13, 2025	Valentine Troy RobertDirector	Stock Award(Grant) at price 0.00 per share.	11.30M	—
Nov 13, 2025	Swan JosephChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	869.6K	—
Nov 13, 2025	Swan JosephDirector	Stock Award(Grant) at price 0.00 per share.	1.69M	—
Nov 13, 2025	Widdows PeterDirector	Stock Award(Grant) at price 0.00 per share.	1.69M	—
Oct 22, 2024	Swan JosephOfficer	Stock Award(Grant) at price 0.00 per share.	100.5K	—

IXHL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IXHL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Incannex Healthcare Inc.

Seasonality · IXHL

Insider Activity · IXHL

Congress Trades · IXHL

Investors Holding IXHL

Investors Holding IXHL

Congress Trades · IXHL

Seasonality · IXHL

Insider Activity · IXHL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Incannex Healthcare Inc.

Financial Snapshot

Earnings & Dividends

News